Amicogen Partner Raisando AG Signs Medolysin Supply Contract with Gulf Cooperation Council

Amicogen (CEO Park Cheol), a specialized company in bio pharmaceuticals and bio materials, announced on the 29th that its partner Lysando AG has signed a supply contract for the innovative wound treatment ‘Medolysin’ in Kuwait. This contract targets the Gulf Cooperation Council Arab States Group (CCASG) countries and is expected to be a significant milestone in improving healthcare services in the Middle East region.

Medolysin is an innovative wound treatment developed by Lysando AG, containing endolysins developed through its proprietary ‘Artilysin technology.’ It effectively eliminates pathogens at the infection site and reduces inflammation. Notably, Medolysin uses a different mechanism from conventional antibiotic treatments for infected wounds and is a natural antibiotic that can address the issue of multidrug-resistant antibiotics.

Lysando AG is a German company headquartered in Switzerland with R&D and sales headquarters in Germany. It is a global leader in the field of next-generation antibiotic candidates, endolysins, holding 260 international patents and 450 candidates. This contract was signed with ‘Al-Sareh International General Trading Co.,’ a company well known for selecting products that provide long-term growth and profitability, fostering sustainable growth between suppliers and consumers.

Amicogen, as Lysando AG’s CDMO partner, will exclusively manufacture and supply Medolysin. Through this collaboration, it is expected to play a pivotal role in supplying innovative wound treatments to the Middle East and global markets.

Meanwhile, in recent years, Middle Eastern countries have made substantial investments in introducing new technologies and innovative products to strengthen medical infrastructure. The Middle Eastern wound treatment market was estimated to be about $100 million in 2021, with a steady growth rate of 6-8% annually. In this context, Medolysin, produced by Amicogen for Lysando AG, is gaining attention as a new solution for treating chronic inflammation caused by infections. Along with the growth of the Middle Eastern wound treatment market, the continuous introduction of innovative products like Medolysin is expected to significantly contribute to improving patients’ quality of life. The strategic partnership between Amicogen and Lysando AG is anticipated to drive continuous innovation and growth for both companies in the future.

This content was produced with the assistance of AI translation services.